Viatris Inc.

Viatris Inc.

VTRSNYSE / NASDAQHealthcareLarge cap

$19.63-$0.25 (-1.3%)

Last close · Data as of Nov 20, 2026

Market cap
$18.5B
Revenue
$14.3B
Net margin
-24.6%
ROCE
-11.0%

+92.6% over the last year

Viatris Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
+5.3%
3M
+21.8%
6M
+18.3%
1Y
+92.6%
5Y
+50.1%

52-week range

Day change -$0.25 (-1.3%) from $20 to $20 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in VTRS, bought on each weekday since 2021.

News & filings

What Viatris filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernThe company made a net loss of 3.5 billion US dollars in fiscal 2025.

Strengths (1)

  • Free cash flow in fiscal 2025 equals 10.0% of the company's market value.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. It operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The company offers prescription brand drugs, generic drugs, complex generic drugs, and biosimilars.

Read moreShow less

Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. It operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The company offers prescription brand drugs, generic drugs, complex generic drugs, and biosimilars. It also provides drugs in various therapeutic areas covering various noncommunicable and infectious diseases, including cardiovascular, CNS and anesthesia, dermatology, diabetes and metabolism, eye care, gastroenterology, immunology, oncology, and respiratory and allergy, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. In addition, the company offers medicines in the form of oral solid doses, injectables, and complex dosage forms to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. It distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies under the Lyrica, Lipitor, Celebrex, Viagra, Creon, Influvac, Wixela Inhub, EpiPen Auto-Injector, Fraxiparine, Yupelri, Norvasc, Amitiza, Effexor, Lipacreon, Zoloft, Xalabrands, Dymista, Xanax, and Breyna brands. The company has collaboration agreements with Mapi Pharma Ltd. to develop and commercialize long-acting glatiramer acetate depot products and additional products; Revance Therapeutics, Inc. to develop, manufacture, and commercialize a biosimilar to the branded biologic product, BOTOX; and Theravance Biopharma, Inc. to develop and commercialize revefenacin. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.

Sector
Healthcare
Shares outstanding
1.15B

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$18.5B
P/B
1.3x
EV / Sales
2.2x
P/S
1.3x
52-week high
$21.06
52-week low
$10.19

Profitability

Operating margin
1.8%
Net margin
-24.6%
EBITDA margin
-2.8%
ROE
-23.9%
ROCE
-11.0%
ROA
-9.5%
Asset turnover
0.38

Growth

Revenue
$14.3B
Revenue growth, 1Y
-3.0%
Revenue CAGR, 3Y
-4.2%
Net profit growth, 1Y
454.2%
Free cash flow
$1.9B

Solvency

Current ratio
1.38
Debt / Equity
1.00
Debt / Assets
0.40
CFO / Net profit
-0.66
Cash / Market cap
8.2%

Where the revenue went

FY2025 ended in a loss, so the lines are listed rather than drawn as a flow.

LineFY2025
Revenue$14.3B
Cost of revenue$9.3B
Gross profit$5.0B
Operating expenses$4.8B
Research and development$965.9M
Selling, general and administrative$3.8B
Operating income$253.5M
Interest and other-$3.9B
Pretax income-$3.7B
Tax and other-$150.1M
Net income-$3.5B

Revenue and net profit

Revenue fell 3.0% in FY2025; net profit is the dashed line.

Viatris Inc. revenue and net profit by fiscal year
Viatris Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$16.3B$2.1B
FY2023$15.4B$54.7M
FY2024$14.7B-$634.2M
FY2025$14.3B-$3.5B

Cash flows

FY2025: $2.3B from operations, $1.9B free after investment (dashed).

Viatris Inc. operating and free cash flow by fiscal year
Viatris Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022$3.0B$2.5B
FY2023$2.9B$2.3B
FY2024$2.3B$1.9B
FY2025$2.3B$1.9B

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$14.3B-3.0%1Y
EBITDA
-$395.4M-114.0%1Y
Net profit
-$3.5B
Cash from operations
$2.3B+0.6%1Y
Free cash flow
$1.9B-4.8%1Y
Revenue CAGR, 3Y
-4.2%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$14.3B-$395.4M-$3.5B$1.9B-23.9%-3.0%+454.2%

Monthly returns

Month-by-month returns of VTRS across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$37.2B
Liabilities$22.5B
Equity$14.7B
Paid-in capital$18.8B
Retained earnings-$388.3M
Treasury stock$1.0B

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; VTRS highlighted.

P/E against peers

VTRS has no positive P/E; the peer median is 22.8x.

Not shown (no positive earnings and no EV / Sales): Viatris Inc., Insmed Incorporated, Moderna, Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Viatris Inc.VTRSthis company$18.5B—1.3x-23.9%—
Insmed IncorporatedINSM$22.7B-17.8x30.8x-172.8%—
West Pharmaceutical Services, Inc.WST$22.4B45.4x7.1x15.5%28.4x
Quest Diagnostics IncorporatedDGX$21.7B21.9x3.0x13.8%12.9x
Labcorp Holdings Inc.LH$21.4B24.4x2.5x10.2%13.6x
STERIS plcSTE$20.7B26.5x2.9x10.9%14.0x
Moderna, Inc.MRNA$20.5B-7.3x2.4x-32.6%-7.5x
Incyte CorporationINCY$20.2B15.7x3.9x24.9%9.8x
Zimmer Biomet Holdings, Inc.ZBH$16.8B23.8x1.3x5.6%10.7x
Peer median—22.8x3.0x10.5%12.9x

Year-to-date ROI

VTRS since 1 January, against earlier years.

Historical volatility

VTRS's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

Viatris Inc. operating margin by fiscal year
Viatris Inc. operating margin by fiscal year
DateOperating margin
FY202210.2%
FY202310.1%
FY20244.8%
FY20251.8%
LineFY2025
Cost of revenueCost Of Revenue$9.3B
Gross profitGross Profit$5.0B
Operating expensesOperating Expense$4.8B
Research and developmentResearch And Development$965.9M
Selling, general and administrativeSelling General And Administration$3.8B
Total expensesTotal Expenses$14.0B
Pretax incomePretax Income-$3.7B

Learn while you research

Academy chapters picked for Viatris Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  3. 03 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  4. 04 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →